ARTICLE | Top Story
NewLink lands $150M upfront from Genentech
October 21, 2014 2:38 AM UTC
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) acquired exclusive, worldwide rights to cancer candidate NLG919 from NewLink Genetics Corp. (NASDAQ:NLNK) for $150 million up front. NewLink is eligible for more than $1 billion in milestones, plus escalating double-digit royalties, and retains co-commercialization rights in the U.S.
NLG919 is an oral small molecule indoleamine 2,3-dioxygenase (INDO; IDO) pathway inhibitor that is in Phase I testing to treat recurrent advanced solid tumors. NewLink declined to disclose when it expects data from the study, which began in December 2013. ...